Cost‐effectiveness of treating all hepatitis B–positive individuals in the United States
Devin Razavi‐Shearer(University of Health Sciences Antigua), Homie Razavi(Center for Disease Analysis), Ivane Gamkrelidze, Chris Estes(Center for Disease Analysis)
Cited by 27
Related Papers
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
|Hepatology|2017|2.4k
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
|The Lancet. Gastroenterology & hepatology|2023|399